Alpha-Methyldopa-Induced Autoimmune Hemolytic Anemia in the Third Trimester of Pregnancy | Zendy

C Grigoriadis | Zendy; Aliki Tympa | Zendy; Angelos Liapis | Zendy; Dimitrios Hassiakos | Zendy; Panagiotis Bakas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alpha-Methyldopa-Induced Autoimmune Hemolytic Anemia in the Third Trimester of Pregnancy

Author(s) -

C Grigoriadis,

Aliki Tympa,

Angelos Liapis,

Dimitrios Hassiakos,

Panagiotis Bakas

Publication year - 2013

Publication title -

case reports in obstetrics and gynecology

Language(s) - English

Resource type - Journals

eISSN - 2090-6684

pISSN - 2090-6692

DOI - 10.1155/2013/150278

Subject(s) - medicine , methyldopa , autoimmune hemolytic anemia , pregnancy , third trimester , second trimester , hemolytic anemia , first trimester , anemia , obstetrics , pharmacology , fetus , immunology , genetics , biology , blood pressure

Alpha-methyldopa has been demonstrated to be safe for use during pregnancy and is now used to treat gestational hypertension. In pregnancy, alpha-methyldopa-induced autoimmune hemolytic anemia does not have typical features and the severity of symptoms ranges from mild fatigue to dyspnea, respiratory failure, and death if left untreated. A case of alpha-methyldopa-induced autoimmune hemolytic anemia in a 36-year-old gravida 2, para 1 woman at 37 +6 weeks of gestation is reported herein along with the differential diagnostic procedure and the potential risks to the mother and the fetus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research